Trial Profile

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimesna (Primary) ; Carboplatin; Pemetrexed
Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms HARMONIC; Harmonica
Sponsors Lantern Pharma

14 Aug 2026 Results presented in the Lantern Pharma media release.
15 May 2026 According to a Lantern Pharma media release, the additional clinical data updates from the trial are expected in the second half of 2026.
15 May 2026 Results presented in the Lantern Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com